Skip to main navigation Skip to search Skip to main content

Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial

  • Thomas R. Meinel
  • , Johannes Kaesmacher
  • , Lukas Buetikofer
  • , Daniel Strbian
  • , Omer Faruk Eker
  • , Christophe Cognard
  • , Pasquale Mordasini
  • , Sandro Deppeler
  • , Vitor Mendes Pereira
  • , Jean François Albucher
  • , Jean Darcourt
  • , Romain Bourcier
  • , Benoit Guillon
  • , Chrysanthi Papagiannaki
  • , Guillaume Costentin
  • , Gerli Sibolt
  • , Silja Räty
  • , Benjamin Gory
  • , Sébastien Richard
  • , Jan Liman
  • Marielle Ernst, Marion Boulanger, Charlotte Barbier, Laura Mechtouff, Liqun Zhang, Gaultier Marnat, Igor Sibon, Omid Nikoubashman, Arno Reich, Arturo Consoli, David Weisenburger, Manuel Requena, Alvaro Garcia-Tornel, Suzana Saleme, Solène Moulin, Paolo Pagano, Guillaume Saliou, Emmanuel Carrera, Kevin Janot, Marti Boix, Raoul Pop, Lucie Della Schiava, Andreas Luft, Michel Piotin, Jean Christophe Gentric, Aleksandra Pikula, Waltraud Pfeilschifter, Marcel Arnold, Adnan Siddiqui, Michael T. Froehler, Anthony J. Furlan, René Chapot, Martin Wiesmann, Paolo MacHi, Hans Christoph Diener, Zsolt Kulcsar, Leo Bonati, Claudio Bassetti, Simon Escalard, David Liebeskind, Jeffrey L. Saver, Urs Fischer, Jan Gralla
  • University of Bern
  • Helsinki University Hospital
  • Hospices civils de Lyon
  • CHU de Toulouse
  • Toronto Western Hospital
  • Nantes University Hospital
  • CHU Hôpitaux de Rouen
  • Université de Lorraine
  • Klinikum Nurnberg
  • University of Göttingen
  • University Caen Normandie
  • St George's University Hospitals NHS Foundation Trust
  • Université de Bordeaux
  • RWTH Aachen University
  • Hôpital Foch
  • Hospital Vall d'Heborn
  • CHU de Limoges
  • CHU de Reims
  • University of Lausanne
  • University of Geneva
  • Université de Tours
  • Generalitat de Catalunya
  • Strasbourg University Hospitals
  • Centre Hospitalier Universitaire de Lille
  • University of Zurich
  • Cereneo Center for Neurology and Rehabilitation
  • Rothschild Foundation Hospital
  • CHU de Brest
  • Goethe University Frankfurt
  • Vanderbilt University
  • Case Western Reserve University
  • Alfried Krupp Krankenhaus
  • Biometry and Epidemiology (IMIBE)
  • University of Basel
  • University of California at Los Angeles

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background We hypothesized that treatment delays might be an effect modifier regarding risks and benefits of intravenous thrombolysis (IVT) before mechanical thrombectomy (MT). Methods We used the dataset of the SWIFT-DIRECT trial, which randomized 408 patients to IVT+MT or MT alone. Potential interactions between assignment to IVT+MT and expected time from onset-to-needle (OTN) as well as expected time from door-to-needle (DTN) were included in regression models. The primary outcome was functional independence (modified Rankin Scale (mRS) 0-2) at 3 months. Secondary outcomes included mRS shift, mortality, recanalization rates, and (symptomatic) intracranial hemorrhage at 24 hours. Results We included 408 patients (IVT+MT 207, MT 201, median age 72 years (IQR 64-81), 209 (51.2%) female). The expected median OTN and DTN were 142 min and 54 min in the IVT+MT group and 129 min and 51 min in the MT alone group. Overall, there was no significant interaction between OTN and bridging IVT assignment regarding either the functional (adjusted OR (aOR) 0.76, 95% CI 0.45 to 1.30) and safety outcomes or the recanalization rates. Analysis of in-hospital delays showed no significant interaction between DTN and bridging IVT assignment regarding the dichotomized functional outcome (aOR 0.48, 95% CI 0.14 to 1.62), but the shift and mortality analyses suggested a greater benefit of IVT when in-hospital delays were short. Conclusions We found no evidence that the effect of bridging IVT on functional independence is modified by overall or in-hospital treatment delays. Considering its low power, this subgroup analysis could have missed a clinically important effect, and exploratory analysis of secondary clinical outcomes indicated a potentially favorable effect of IVT with shorter in-hospital delays. Heterogeneity of the IVT effect size before MT should be further analyzed in individual patient meta-analysis of comparable trials. Trial registration number URL: https://www.clinicaltrials.gov;

Original languageEnglish
Pages (from-to)E102-E110
JournalJournal of NeuroInterventional Surgery
Volume15
Issue numbere1
DOIs
StatePublished - Sep 1 2023

Keywords

  • Thrombectomy
  • Thrombolysis

Fingerprint

Dive into the research topics of 'Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial'. Together they form a unique fingerprint.

Cite this